An Analysis of the DEVELOP Registry: A multicenter, global, prospective, observational registry study of infliximab dose escalation in pediatric patients with crohn's disease or ulcerative colitis
Latest Information Update: 29 Feb 2024
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms DEVELOP Registry
- 22 Dec 2021 New trial record
- 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021